The integration of genomics testing and functional proteomics in the era of personalized medicine
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The integration of genomics testing and functional proteomics in the era of personalized medicine
Authors
Keywords
-
Journal
Expert Review of Proteomics
Volume 14, Issue 12, Pages 1055-1058
Publisher
Informa UK Limited
Online
2017-10-17
DOI
10.1080/14789450.2017.1392245
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
- (2017) Kenichi Suda et al. Journal of Thoracic Oncology
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
- (2017) H Zhou et al. LEUKEMIA
- The evolving genomic landscape of urothelial carcinoma
- (2017) Alexander P. Glaser et al. Nature Reviews Urology
- A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
- (2017) Michael Michael et al. Targeted Oncology
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- (2017) Christophe Massard et al. Cancer Discovery
- Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases
- (2017) Stephanie U. Greer et al. Genome Medicine
- Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
- (2016) Priya Chudasama et al. CLINICAL CANCER RESEARCH
- First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation
- (2016) R. Kim et al. EUROPEAN JOURNAL OF CANCER
- Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives
- (2016) Li Zhou et al. Expert Review of Proteomics
- Clinical implications of recent advances in proteogenomics
- (2016) Marie Locard-Paulet et al. Expert Review of Proteomics
- Mission critical: the need for proteomics in the era of next-generation sequencing and precision medicine
- (2016) Devon M. Cayer et al. HUMAN MOLECULAR GENETICS
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Proteogenomics connects somatic mutations to signalling in breast cancer
- (2016) Philipp Mertins et al. NATURE
- Precision medicine in cardiology
- (2016) Elliott M. Antman et al. Nature Reviews Cardiology
- Limits to Personalized Cancer Medicine
- (2016) Ian F. Tannock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutics Targeting FGF Signaling Network in Human Diseases
- (2016) Masaru Katoh TRENDS IN PHARMACOLOGICAL SCIENCES
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
- (2016) A. Pearson et al. Cancer Discovery
- Development and clinical application of an integrative genomic approach to personalized cancer therapy
- (2016) Andrew V. Uzilov et al. Genome Medicine
- Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
- (2016) Terence G. Hall et al. PLoS One
- Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes
- (2015) Marta Pelay-Gimeno et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
- (2015) Fabrice André et al. BREAST CANCER RESEARCH AND TREATMENT
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells
- (2015) Y. Kwak et al. MOLECULAR CANCER THERAPEUTICS
- A New Initiative on Precision Medicine
- (2015) Francis S. Collins et al. NEW ENGLAND JOURNAL OF MEDICINE
- Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
- (2015) Daniela Sia et al. Nature Communications
- First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
- (2015) M. Hagel et al. Cancer Discovery
- Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors
- (2015) Daniel H. Hovelson et al. NEOPLASIA
- Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
- (2015) Jinjia Chang et al. Oncotarget
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells
- (2014) J Wang et al. ONCOGENE
- What is personalized medicine: sharpening a vague term based on a systematic literature review
- (2013) Sebastian Schleidgen et al. BMC Medical Ethics
- FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
- (2013) L. Xie et al. CLINICAL CANCER RESEARCH
- FGF Receptors: Cancer Biology and Therapeutics
- (2013) Masaru Katoh et al. MEDICINAL RESEARCH REVIEWS
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Targeted Disruption of the BCL9/ -Catenin Complex Inhibits Oncogenic Wnt Signaling
- (2012) K. Takada et al. Science Translational Medicine
- ALKoma: A Cancer Subtype with a Shared Target
- (2012) Hiroyuki Mano Cancer Discovery
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started